Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06378047 · ClinicalTrials.gov registry record · Phase 1
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT06378047: Completed Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06378047 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06378047, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).
Primary Outcome
The number of participants who experience a high-grade (grade 3-5) adverse events based on NCI common terminology criteria for adverse events (CTCAE) version 5 related to treatment.
Interventions
- DRUG Pembrolizumab
- DEVICE Irreversible Electroporation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2025-09-15 |
| Phase | Phase 1 |
What the finished NCT06378047 record still lists
NCT06378047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06378047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06378047 about?
NCT06378047 is a clinical study titled "Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer". This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic re...
What is the current status of trial NCT06378047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2024-04-10. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT06378047?
The interventions under investigation include: Pembrolizumab (DRUG), Irreversible Electroporation (DEVICE).
Who is sponsoring clinical trial NCT06378047?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06378047's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI